In 2013, a clutch of concepts about monoclonal antibody (MAb)-based discovery that had been incubated at life science investment firm Orbimed Advisors was quietly placed into the startup Compass Therapeutics LLC, which launched a year later with about $1 million in seed funding from Orbimed. From the get-go, Compass viewed MAb-based discovery, especially in immunology, through a different lens than most traditional drug developers, recalled Thomas Schuetz, an Orbimed entrepreneur-in-residence who co-founded Compass and serves as its CEO.